"{\n \"business_address\": \"ONE BECTON DR, FRANKLIN LAKES, NJ 07417-1880\", \n \"business_phone_no\": \"2018476800\", \n \"ceo\": \"Vincent A. Forlenza\", \n \"cik\": \"0000010795\", \n \"company_url\": \"www.bd.com\", \n \"employees\": 50900, \n \"entity_legal_form\": null, \n \"entity_status\": null, \n \"hq_address1\": null, \n \"hq_address2\": null, \n \"hq_address_city\": null, \n \"hq_address_postal_code\": null, \n \"hq_country\": \"United States of America\", \n \"hq_state\": \"New Jersey\", \n \"inc_country\": \"United States of America\", \n \"inc_state\": \"New Jersey\", \n \"industry_category\": \"Health Services\", \n \"industry_group\": \"Medical Instruments & Supplies\", \n \"latest_filing_date\": \"2017-08-03\", \n \"legal_name\": \"BECTON DICKINSON & CO\", \n \"lei\": \"ICE2EP6D98PQUILVRZ91\", \n \"long_description\": \"Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and IV sets for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laproscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; and prefillable drug delivery systems. The BD Life Sciences segment provides integrated systems for specimen collection; safety-engineered blood collection, automated blood culturing and tuberculosis culturing, and microorganism identification and drug susceptibility systems; molecular testing systems for infectious diseases and women's health; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation, and plated media products; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. The company markets its products through independent distribution channels and sales representatives to healthcare institutions, life science researchers, clinical laboratories, pharmaceutical industry, and general public. Becton, Dickinson and Company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.\", \n \"mailing_address\": \"ONE BECTON DR, FRANKLIN LAKE, NJ 07417\", \n \"name\": \"Becton Dickinson and Co\", \n \"sector\": \"Healthcare\", \n \"securities\": [\n  {\n   \"composite_figi\": \"BBG000BCZYD3\", \n   \"composite_figi_ticker\": \"BDX:US\", \n   \"currency\": \"USD\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XNYS\", \n   \"figi\": \"BBG000BCZYD3\", \n   \"figi_exch_cntry\": \"US\", \n   \"figi_ticker\": \"BDX:US\", \n   \"figi_uniqueid\": \"EQ0010018300001000\", \n   \"last_crsp_adj_date\": \"2017-09-07\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XNYS\", \n   \"primary_listing\": true, \n   \"security_name\": \"BECTON DICKINSON AND CO\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S5P374\", \n   \"stock_exchange\": \"NYSE\", \n   \"ticker\": \"BDX\"\n  }, \n  {\n   \"composite_figi\": \"BBG000DXDG48\", \n   \"composite_figi_ticker\": \"BOX:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XFRA\", \n   \"figi\": \"BBG000DXDGQ4\", \n   \"figi_exch_cntry\": \"GF\", \n   \"figi_ticker\": \"BOX:GF\", \n   \"figi_uniqueid\": \"EQ0010018300001001\", \n   \"last_crsp_adj_date\": \"2017-09-07\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XFRA\", \n   \"primary_listing\": false, \n   \"security_name\": \"BECTON DICKINSON AND CO\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S5P374\", \n   \"stock_exchange\": \"FRA\", \n   \"ticker\": \"BOX\"\n  }, \n  {\n   \"composite_figi\": \"BBG000DXDG48\", \n   \"composite_figi_ticker\": \"BOX:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XBER\", \n   \"figi\": \"BBG000DXDJY9\", \n   \"figi_exch_cntry\": \"GB\", \n   \"figi_ticker\": \"BOX:GB\", \n   \"figi_uniqueid\": \"EQ0010018300001001\", \n   \"last_crsp_adj_date\": \"2017-09-07\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XBER\", \n   \"primary_listing\": false, \n   \"security_name\": \"BECTON, DICKINSON AND CO.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S5P374\", \n   \"stock_exchange\": \"BER\", \n   \"ticker\": \"BOX\"\n  }, \n  {\n   \"composite_figi\": \"BBG000DXDG48\", \n   \"composite_figi_ticker\": \"BOX:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XMUN\", \n   \"figi\": \"BBG000DXDJQ8\", \n   \"figi_exch_cntry\": \"GM\", \n   \"figi_ticker\": \"BOX:GM\", \n   \"figi_uniqueid\": \"EQ0010018300001001\", \n   \"last_crsp_adj_date\": \"2017-09-07\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XMUN\", \n   \"primary_listing\": false, \n   \"security_name\": \"BECTON, DICKINSON AND CO.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S5P374\", \n   \"stock_exchange\": \"MUN\", \n   \"ticker\": \"BOX\"\n  }, \n  {\n   \"composite_figi\": \"BBG000DXDG48\", \n   \"composite_figi_ticker\": \"BOX:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XDUS\", \n   \"figi\": \"BBG000DXDH91\", \n   \"figi_exch_cntry\": \"GD\", \n   \"figi_ticker\": \"BOX:GD\", \n   \"figi_uniqueid\": \"EQ0010018300001001\", \n   \"last_crsp_adj_date\": \"2017-09-07\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XDUS\", \n   \"primary_listing\": false, \n   \"security_name\": \"BECTON, DICKINSON AND CO.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S5P374\", \n   \"stock_exchange\": \"DUS\", \n   \"ticker\": \"BOX\"\n  }, \n  {\n   \"composite_figi\": \"BBG000DXDG48\", \n   \"composite_figi_ticker\": \"BOX:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XETR\", \n   \"figi\": \"BBG000DXDG48\", \n   \"figi_exch_cntry\": \"GR\", \n   \"figi_ticker\": \"BOX:GR\", \n   \"figi_uniqueid\": \"EQ0010018300001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XETR\", \n   \"primary_listing\": false, \n   \"security_name\": \"BECTON, DICKINSON AND CO.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S5P374\", \n   \"stock_exchange\": \"XETRA\", \n   \"ticker\": \"BOX\"\n  }, \n  {\n   \"composite_figi\": \"BBG007FJNTB5\", \n   \"composite_figi_ticker\": \"BDX:SW\", \n   \"currency\": \"CHF\", \n   \"delisted_security\": true, \n   \"etf\": false, \n   \"exch_symbol\": \"^XSWX\", \n   \"figi\": \"BBG007FJNTD3\", \n   \"figi_exch_cntry\": \"SE\", \n   \"figi_ticker\": \"BDX:SE\", \n   \"figi_uniqueid\": \"EQ0000000038430481\", \n   \"last_crsp_adj_date\": \"2017-08-17\", \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XSWX\", \n   \"primary_listing\": false, \n   \"security_name\": \"BECTON DICKINSON AND CO\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S5P374\", \n   \"stock_exchange\": \"SIX\", \n   \"ticker\": \"BDX\"\n  }, \n  {\n   \"composite_figi\": \"BBG000DXDG48\", \n   \"composite_figi_ticker\": \"BOX:GR\", \n   \"currency\": \"EUR\", \n   \"delisted_security\": false, \n   \"etf\": false, \n   \"exch_symbol\": \"^XSTU\", \n   \"figi\": \"BBG000DXDJ79\", \n   \"figi_exch_cntry\": \"GS\", \n   \"figi_ticker\": \"BOX:GS\", \n   \"figi_uniqueid\": \"EQ0010018300001001\", \n   \"last_crsp_adj_date\": null, \n   \"market_sector\": \"Equity\", \n   \"mic\": \"XSTU\", \n   \"primary_listing\": false, \n   \"security_name\": \"BECTON, DICKINSON AND CO.\", \n   \"security_type\": \"Common Stock\", \n   \"share_class_figi\": \"BBG001S5P374\", \n   \"stock_exchange\": \"STU\", \n   \"ticker\": \"BOX\"\n  }\n ], \n \"short_description\": \"Becton, Dickinson & Co. is a global medical technology company. The company is engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The company operates through two worldwide business segments: BD Medical and BD Life Sciences. The BD Medical segment produces medical devices that are used in healthcare settings. This segment product includes needles, syringes and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for the self-injection of insulin and other drugs used in the treatment of diabetes. The BD Life Sciences segment produces products for the safe collection and transport of diagnostic specimens, as well as instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The segment also produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. The principal products and services in the Life Sciences segment include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing and tuberculosis culturing systems; molecular testing systems for infectious diseases and women's health; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation; plated media; fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; molecular indexing and next-generation sequencing sample preparation for genomics research; clinical oncology, immunology and transplantation diagnostic/monitoring reagents and analyzers; and cell culture media supplements for biopharmaceutical manufacturing. Becton, Dickinson & Co. was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.\", \n \"sic\": 3841, \n \"standardized_active\": true, \n \"stock_exchange\": \"NYSE\", \n \"template\": \"industrial\", \n \"ticker\": \"BDX\"\n}"